Last reviewed · How we verify

NCT05839509

Phase 2 Clinical Trial of GH001 in Bipolar II Disorder

Terminated Phase 2 Last updated 18 February 2025
What this trial tests

Phase 2 trial testing GH001 in Bipolar II Disorder in 6 participants. Terminated before completion.

Timeline
6 April 2023
Primary endpoint
13 November 2024
5 December 2024

Quick facts

Lead sponsorGH Research Ireland Limited
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment6
Start date6 April 2023
Primary completion13 November 2024
Estimated completion5 December 2024
Sites7 locations across United Kingdom, Netherlands, Germany

Drugs / interventions tested

Conditions studied

Sponsor

GH Research Ireland Limited — full company profile →

Who can join

Adults 18 to 64, any sex, with Bipolar II Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a current episode of depression will be included in this study. The participants will receive an individualized dosing regimen (IDR) with at least one and up to three doses of GH001 administered within a single day.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The possible place for psychedelics in pharmacotherapy of mental disorders.
    Wojtas A. · · 2023 · cited 7× · PMID 37934320 · DOI 10.1007/s43440-023-00550-9
  2. Molecular, haemodynamic and functional effects of LSD in the human brain
    McCulloch DE, Larsen K, Johansen A, Reveles Jensen KH, et al · · 2025 · DOI 10.1101/2025.06.17.25329677

Verify or expand the search:

Other trials of GH001

Trials testing the same drug.

Other recruiting trials for Bipolar II Disorder

Currently open trials in the same condition.

Other GH Research Ireland Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05839509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing